loading
Schlusskurs vom Vortag:
$2.76
Offen:
$2.73
24-Stunden-Volumen:
48,073
Relative Volume:
0.63
Marktkapitalisierung:
$59.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.94M
KGV:
-0.9197
EPS:
-2.84
Netto-Cashflow:
$-13.83M
1W Leistung:
-21.75%
1M Leistung:
-27.45%
6M Leistung:
-31.30%
1J Leistung:
+42.31%
1-Tages-Spanne:
Value
$2.55
$2.8501
1-Wochen-Bereich:
Value
$2.55
$3.455
52-Wochen-Spanne:
Value
$1.61
$7.42

Aileron Therapeutics Inc Stock (ALRN) Company Profile

Name
Firmenname
Aileron Therapeutics Inc
Name
Telefon
(737) 802-1989
Name
Adresse
12407 N. MOPAC EXPY., AUSTIN, MA
Name
Mitarbeiter
3
Name
Twitter
@Aileron_org
Name
Nächster Verdiensttermin
2024-11-18
Name
Neueste SEC-Einreichungen
Name
ALRN's Discussions on Twitter

Vergleichen Sie ALRN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
ALRN 2.59 59.80M 0 -12.94M -13.83M -2.84
VRTX 450.00 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.66 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 588.46 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 248.13 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.53 24.89B 3.30B -501.07M 1.03B 11.54

Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2017-07-24 Eingeleitet BofA/Merrill Buy
2017-07-24 Eingeleitet Jefferies Buy
2017-07-24 Eingeleitet William Blair Outperform

Aileron Therapeutics Inc Aktie (ALRN) Neueste Nachrichten

pulisher
Nov 20, 2024

Aileron Therapeutics Reports Q3 2024 Financial Results - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Citizentribune

Nov 19, 2024
pulisher
Nov 17, 2024

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in October - MarketBeat

Nov 17, 2024
pulisher
Nov 15, 2024

Aileron Therapeutics Inc (ALRN) Quarterly 10-Q Report - Quartz

Nov 15, 2024
pulisher
Nov 14, 2024

Aileron Reports Positive Phase 1b Data for IPF Drug, Shows Strong Biomarker Response | ALRN Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis - AOL

Nov 13, 2024
pulisher
Nov 13, 2024

Aileron reports promising phase 1b trial results for IPF treatment - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Aileron reports promising phase 1b trial results for IPF treatment By Investing.com - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Yahoo Finance

Nov 13, 2024
pulisher
Nov 01, 2024

Advancium explores ALRN-6924 for pediatric eye cancer treatment - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

Advancium explores ALRN-6924 for pediatric eye cancer treatment By Investing.com - Investing.com Canada

Nov 01, 2024
pulisher
Oct 31, 2024

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - PR Newswire

Oct 31, 2024
pulisher
Oct 29, 2024

Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Drops By 14.2% - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Constrained Peptide Drugs Market Size, Scope and Share Analysis - InsightAce Analytic

Oct 28, 2024
pulisher
Oct 14, 2024

Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Increases By 15.8% - MarketBeat

Oct 14, 2024
pulisher
Oct 13, 2024

ALRNAileron Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 13, 2024
pulisher
Oct 12, 2024

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis - Lelezard

Oct 12, 2024
pulisher
Oct 02, 2024

University of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat

Oct 02, 2024
pulisher
Oct 01, 2024

Nantahala Capital Management LLC Raises Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat

Oct 01, 2024
pulisher
Sep 28, 2024

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in September - MarketBeat

Sep 28, 2024
pulisher
Sep 25, 2024

Alumis (NASDAQ:ALMS) Trading 4.8% Higher - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Keeping an Eye on Alx Oncology Holdings Inc (ALXO) After Insider Trading Activity - Knox Daily

Sep 25, 2024
pulisher
Sep 25, 2024

Ready to Jump After Recent Trade: Alx Oncology Holdings Inc (ALXO) - SETE News

Sep 25, 2024
pulisher
Sep 24, 2024

ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Market Highlights: Alector Inc (ALEC) Ends on a Low Note at 5.45 - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News

Sep 24, 2024
pulisher
Sep 23, 2024

Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Alector (NASDAQ:ALEC) Shares Down 5.6% - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Nasdaq

Sep 23, 2024
pulisher
Sep 23, 2024

Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Keith Johns Joins Allurion's Board Of Directors - MPO-mag

Sep 23, 2024
pulisher
Sep 23, 2024

HighVista Strategies LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Healius sells Lumus imaging unit to Affinity for USD 657M - Medical Buyer

Sep 23, 2024
pulisher
Sep 22, 2024

Australia Medical Diagnostics Firm Healius Sells Lumus to Affinity for $657 Million - BNN Bloomberg

Sep 22, 2024
pulisher
Sep 22, 2024

Renaissance Technologies LLC Sells 800 Shares of Alexander’s, Inc. (NYSE:ALX) - Defense World

Sep 22, 2024
pulisher
Sep 21, 2024

Alector (NASDAQ:ALEC) Stock Price Up 9% - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

1,959,896 Shares in Alumis Inc. (NASDAQ:ALMS) Bought by SR One Capital Management LP - MarketBeat

Sep 21, 2024
pulisher
Sep 20, 2024

Aileron Therapeutics Inc Inc. (ALRN) Price Performance: The Role of Supply and Demand - The InvestChronicle

Sep 20, 2024
pulisher
Sep 20, 2024

Closing Bell Recap: Aileron Therapeutics Inc (ALRN) Ends at 2.91, Reflecting a 9.81 Upturn - The Dwinnex

Sep 20, 2024
pulisher
Sep 19, 2024

Altair Engineering: Rating Downgrade As Near-Term Upside Is Limited (NASDAQ:ALTR) - Seeking Alpha

Sep 19, 2024
pulisher
Sep 19, 2024

Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat

Sep 19, 2024
pulisher
Sep 19, 2024

Alesi Surgical wins FDA clearance for smoke management device and lands new funding - Mass Device

Sep 19, 2024
pulisher
Sep 19, 2024

Alector, Inc. (NASDAQ:ALEC) Short Interest Down 5.7% in August - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Allurion Technologies Inc. (NYSE:ALUR) Short Interest Up 8.6% in August - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Australia's ALS tumbles on subdued half-year forecast - XM

Sep 18, 2024
pulisher
Sep 18, 2024

Market cap of Allarity Therapeutics Inc [ALLR] reaches 4.22M – now what? - The DBT News

Sep 18, 2024
pulisher
Sep 18, 2024

Alumis (NASDAQ:ALMS) Stock Price Up 5.3% - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Alexander's (NYSE:ALX) Hits New 52-Week High at $248.10 - MarketBeat

Sep 18, 2024
pulisher
Sep 18, 2024

In the Green: Alector Inc (ALEC) Closes at 5.64, Up/Down -0.70 from Previous Day - The Dwinnex

Sep 18, 2024

Finanzdaten der Aileron Therapeutics Inc-Aktie (ALRN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):